RxDoctor Payments Data

Richard McLean, MD

Internal Medicine · Plantation, FLNPI 1871571158

Payments from drug & device makers

$2,382in general payments, 2019–2025

Across 66 payments — averaging $36.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Sanofi-aventis U.S. LLC$286
  • Boston Scientific$246
  • Stryker$150
  • Lilly USA, LLC$140
  • Novo Nordisk$139
  • plus $324 from 8 others

What the payments were for

  • Food & beverage$2,382100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,382 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$78,215
Medicare patients
75
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol83$87,763
EliquisApixaban31$39,311
XareltoRivaroxaban24$19,144
JanuviaSitagliptin Phosphate20$17,329
TradjentaLinagliptin12$8,375
Valsartan47$1,401
Amlodipine Besylate129$1,144
Nifedipine ErNifedipine41$881
Gabapentin34$822
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$819
Losartan Potassium90$721
Atorvastatin Calcium79$699
Lisinopril97$648
Azelastine Hcl13$587
Rosuvastatin Calcium74$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,097$87,76383 claims
PfizerEliquis$35$39,31131 claims
Johnson & JohnsonXarelto$61$19,14424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →